lobbying_activities: 3432671

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3432671	cbd7af7d-b22d-4149-972c-2affa65895f2	Q3	INFECTIOUS DISEASES SOCIETY OF AMERICA	54836	INFECTIOUS DISEASES SOCIETY OF AMERICA	2025	third_quarter	MED	Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance, FDA proposed regulations regarding laboratory developed tests, House Energy and Commerce NIH RFI, Administration Executive Orders regarding HHS, NIH, HRSA, FDA, and CDC.	Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE		300000	0	0	2025-10-14T16:50:07-04:00